Ethicon and Focal develop cardiovascular sealant:
This article was originally published in Clinica
Johnson & Johnson subsidiary Ethicon and Focal are to jointly develop and market a cardiovascular version of the surgical sealant FocalSeal. The companies are already working on pulmonary and neural versions under an agreement reached last year. FocalSeal is approved outside North America for lung indications and is distributed by Ethicon under the brand name AdvaSeal.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.